Page 101 - Read Online

Ma et al. J Transl Genet Genom 2022;6:179-203 https://dx.doi.org/10.20517/jtgg.2021.48 Page 199

eyedrops. Ophthalmology 2016;123:391-9. DOI PubMed
85. Cho P, Cheung SW. Retardation of myopia in Orthokeratology (ROMIO) study: a 2-year randomized clinical trial. Invest Ophthalmol
Vis Sci 2012;53:7077-85. DOI PubMed
86. Charm J, Cho P. High myopia-partial reduction ortho-k: a 2-year randomized study. Optom Vis Sci 2013;90:530-9. DOI PubMed
87. Walline JJ, Jones LA, Sinnott LT. Corneal reshaping and myopia progression. Br J Ophthalmol 2009;93:1181-5. DOI PubMed
88. Kakita T, Hiraoka T, Oshika T. Influence of overnight orthokeratology on axial elongation in childhood myopia. Invest Ophthalmol
Vis Sci 2011;52:2170-4. DOI PubMed
89. Zhu MJ, Feng HY, He XG, Zou HD, Zhu JF. The control effect of orthokeratology on axial length elongation in Chinese children
with myopia. BMC Ophthalmol 2014;14:141. DOI PubMed PMC
90. Ng DSC, Fung NSK, Yip FLT, Lai TYY. Ranibizumab for myopic choroidal neovascularization. Expert Opin Biol Ther
2020;20:1385-93. DOI PubMed
91. Zhang M, Zhang J, Yan M, et al; KH902 Phase 1 Study Group. A phase 1 study of KH902, a vascular endothelial growth factor
receptor decoy, for exudative age-related macular degeneration. Ophthalmology 2011;118:672-8. DOI
92. Rudge JS, Holash J, Hylton D, et al. VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for
predicting efficacious angiogenic blockade. Proc Natl Acad Sci U S A 2007;104:18363-70. DOI PubMed PMC
93. Wolf S, Balciuniene VJ, Laganovska G, et al; RADIANCE Study Group. RADIANCE: a randomized controlled study of
ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology 2014;121:682-92.e2.
DOI PubMed
94. Chen C, Yan M, Huang Z, Song YP. The evaluation of a two-year outcome of intravitreal conbercept versus ranibizumab for
pathological myopic choroidal neovascularization. Curr Eye Res 2020;45:1415-21. DOI PubMed
95. Ruiz-Moreno JM, Arias L, Montero JA, Carneiro A, Silva R. Intravitreal anti-VEGF therapy for choroidal neovascularisation
secondary to pathological myopia: 4-year outcome. Br J Ophthalmol 2013;97:1447-50. DOI PubMed
96. Ng DSC, Ho M, Iu LPL, Lai TYY. Safety review of anti-VEGF therapy in patients with myopic choroidal neovascularization. Expert
Opin Drug Saf 2022;21:43-54. DOI PubMed
97. Tufail A, Narendran N, Patel PJ, et al. Ranibizumab in myopic choroidal neovascularization: the 12-month results from the REPAIR
study. Ophthalmology 2013;120:1944-5.e1. DOI PubMed
98. Mitchell P, Holz FG, Hykin P, et al; ARIES study investigators. Efficacy and safety of intravitreal aflibercept using a treat-and-
extend regimen for neovascular age-related macular degeneration: the aries study: a randomized clinical trial. Retina 2021;41:1911-
20. DOI
99. Kim YC, Shin JP, Pak KY, et al. Two-year outcomes of the treat-and-extend regimen using aflibercept for treating diabetic macular
oedema. Sci Rep 2020;10:22030. DOI PubMed PMC
100. Hamilton RD, Clemens A, Minnella AM, et al; LUMINOUS study group. Real-world effectiveness and safety of ranibizumab for the
treatment of myopic choroidal neovascularization: Results from the LUMINOUS study. PLoS One 2020;15:e0227557. DOI
PubMed PMC
101. Lai TY, Luk FO, Lee GK, Lam DS. Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with
bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization. Eye (Lond) 2012;26:1004-11.
DOI PubMed PMC
102. Cheung CMG, Arnold JJ, Holz FG, et al. Myopic choroidal neovascularization: review, guidance, and consensus statement on
management. Ophthalmology 2017;124:1690-711. DOI PubMed
103. Verteporfin in Photodynamic Therapy (VIP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in
pathologic myopia with verteporfin. Ophthalmology 2001;108:841-52. DOI PubMed
104. Virgili G, Menchini F. Laser photocoagulation for choroidal neovascularisation in pathologic myopia. Cochrane Database Syst Rev
2005:CD004765. DOI PubMed
105. Iwase T, Ueno Y, Ra E, Ito Y, Terasaki H. Changes in choriocapillaris and retinal morphology after laser photocoagulation by OCT
angiography: A case report. Medicine (Baltimore) 2018;97:e13278. DOI PubMed PMC
106. Pece A, Brancato R, Avanza P, Camesasca F, Galli L. Laser photocoagulation of choroidal neovascularization in pathologic myopia:
long-term results. Int Ophthalmol ;18:339-44. DOI PubMed
107. Brancato R, Menchini U, Pece A, Capoferri C, Avanza P, Radrizzani E. Dye laser photocoagulation of macular subretinal
neovascularization in pathological myopia. A randomized study of three different wavelengths. Int Ophthalmol 1988;11:235-8. DOI
PubMed
108. Secrétan M, Kuhn D, Soubrane G, Coscas G. Long-term visual outcome of choroidal neovascularization in pathologic myopia:
natural history and laser treatment. Eur J Ophthalmol 1997;7:307-316. PubMed
109. Brancato R, Pece A, Avanza P, Radrizzani E. Photocoagulation scar expansion after laser therapy for choroidal neovascularization in
degenerative myopia. Retina 1990;10:239-43. DOI PubMed
110. Parodi M, La Spina C, Berchicci L, Petruzzi G, Bandello F. Photosensitizers and photodynamic therapy: Verteporfin. in: Nguyen Q,
Rodrigues E, Farah M, Mieler W, Do D, editors. Retinal Pharmacotherapeutics. S. Karger AG :2015. pp. 330-6. DOI
111. Schlötzer-Schrehardt U, Viestenz A, Naumann GO, Laqua H, Michels S, Schmidt-Erfurth U. Dose-related structural effects of
photodynamic therapy on choroidal and retinal structures of human eyes. Graefes Arch Clin Exp Ophthalmol 2002;240:748-57. DOI
PubMed